Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Advertisement
Articles by Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.
Advertisement
Latest Updated Articles
Integrase Strand Transfer Inhibitors Associated With Weight Gain in Patients With HIVPublished: July 20th 2020 | Updated:
Non-oral PrEP Options Are Being Investigated to Improve Patient AdherencePublished: November 20th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition
3
Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM
4
Improving Outcomes in Diffuse B-Cell Lymphoma Requires Multidisciplinary Evolution
5
